Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 9/10

vs
industry
vs
history
Cash to Debt No Debt
ABMD's Cash to Debt is ranked higher than
93% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 2.30 vs. ABMD: No Debt )
ABMD' s 10-Year Cash to Debt Range
Min: 31.75   Max: No Debt
Current: No Debt

Equity to Asset 0.81
ABMD's Equity to Asset is ranked higher than
85% of the 467 Companies
in the Global Medical Devices industry.

( Industry Median: 0.65 vs. ABMD: 0.81 )
ABMD' s 10-Year Equity to Asset Range
Min: 0.72   Max: 0.94
Current: 0.81

0.72
0.94
Interest Coverage No Debt
ABMD's Interest Coverage is ranked higher than
94% of the 271 Companies
in the Global Medical Devices industry.

( Industry Median: 365.56 vs. ABMD: No Debt )
ABMD' s 10-Year Interest Coverage Range
Min: 9999.99   Max: 9999.99
Current: No Debt

F-Score: 8
Z-Score: 38.40
M-Score: -2.63
WACC vs ROIC
11.57%
21.83%
WACC
ROIC
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 7/10

vs
industry
vs
history
Operating margin (%) 9.37
ABMD's Operating margin (%) is ranked higher than
83% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 4.63 vs. ABMD: 9.37 )
ABMD' s 10-Year Operating margin (%) Range
Min: -111.48   Max: 10.46
Current: 9.37

-111.48
10.46
Net-margin (%) 8.65
ABMD's Net-margin (%) is ranked higher than
85% of the 486 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ABMD: 8.65 )
ABMD' s 10-Year Net-margin (%) Range
Min: -84.54   Max: 9.5
Current: 8.65

-84.54
9.5
ROE (%) 10.59
ABMD's ROE (%) is ranked higher than
86% of the 477 Companies
in the Global Medical Devices industry.

( Industry Median: 3.61 vs. ABMD: 10.59 )
ABMD' s 10-Year ROE (%) Range
Min: -46.87   Max: 11.4
Current: 10.59

-46.87
11.4
ROA (%) 8.69
ABMD's ROA (%) is ranked higher than
90% of the 513 Companies
in the Global Medical Devices industry.

( Industry Median: 0.75 vs. ABMD: 8.69 )
ABMD' s 10-Year ROA (%) Range
Min: -42.19   Max: 9.27
Current: 8.69

-42.19
9.27
ROC (Joel Greenblatt) (%) 100.17
ABMD's ROC (Joel Greenblatt) (%) is ranked higher than
98% of the 510 Companies
in the Global Medical Devices industry.

( Industry Median: 5.44 vs. ABMD: 100.17 )
ABMD' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -294.77   Max: 90.23
Current: 100.17

-294.77
90.23
Revenue Growth (3Y)(%) 17.50
ABMD's Revenue Growth (3Y)(%) is ranked higher than
93% of the 343 Companies
in the Global Medical Devices industry.

( Industry Median: 4.20 vs. ABMD: 17.50 )
ABMD' s 10-Year Revenue Growth (3Y)(%) Range
Min: -7.2   Max: 18.4
Current: 17.5

-7.2
18.4
» ABMD's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

ABMD Guru Trades in Q1 2014

Steven Cohen 11,972 sh (New)
Paul Tudor Jones 11,200 sh (New)
Joel Greenblatt 25,692 sh (New)
PRIMECAP Management 5,751,990 sh (unchged)
Jim Simons Sold Out
» More
Q2 2014

ABMD Guru Trades in Q2 2014

Chase Coleman 1,690,000 sh (New)
Jim Simons 97,223 sh (New)
Paul Tudor Jones Sold Out
Joel Greenblatt Sold Out
PRIMECAP Management 5,726,490 sh (-0.44%)
» More
Q3 2014

ABMD Guru Trades in Q3 2014

Chase Coleman 1,690,000 sh (unchged)
Jim Simons Sold Out
PRIMECAP Management 5,664,990 sh (-1.07%)
» More
Q4 2014

ABMD Guru Trades in Q4 2014

Joel Greenblatt 22,440 sh (New)
PRIMECAP Management 5,687,590 sh (+0.40%)
Chase Coleman Sold Out
» More
» Details

Insider Trades

Latest Guru Trades with ABMD

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
P/E(ttm) 154.80
ABMD's P/E(ttm) is ranked higher than
70% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 154.80 )
ABMD' s 10-Year P/E(ttm) Range
Min: 36.46   Max: 946.92
Current: 154.8

36.46
946.92
Forward P/E 83.33
ABMD's Forward P/E is ranked higher than
72% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 83.33 )
N/A
PE(NRI) 154.50
ABMD's PE(NRI) is ranked higher than
76% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 154.50 )
ABMD' s 10-Year PE(NRI) Range
Min: 36.03   Max: 820.67
Current: 154.5

36.03
820.67
P/B 14.00
ABMD's P/B is ranked lower than
62% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 4.40 vs. ABMD: 14.00 )
ABMD' s 10-Year P/B Range
Min: 1.58   Max: 14.76
Current: 14

1.58
14.76
P/S 13.38
ABMD's P/S is ranked lower than
67% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 4.29 vs. ABMD: 13.38 )
ABMD' s 10-Year P/S Range
Min: 2.38   Max: 13.89
Current: 13.38

2.38
13.89
PFCF 88.40
ABMD's PFCF is ranked higher than
75% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 88.40 )
ABMD' s 10-Year PFCF Range
Min: 23.56   Max: 2462
Current: 88.4

23.56
2462
POCF 82.91
ABMD's POCF is ranked higher than
77% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 82.91 )
ABMD' s 10-Year POCF Range
Min: 21.88   Max: 463.25
Current: 82.91

21.88
463.25
EV-to-EBIT 138.70
ABMD's EV-to-EBIT is ranked higher than
73% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 138.70 )
ABMD' s 10-Year EV-to-EBIT Range
Min: -305.5   Max: 694.7
Current: 138.7

-305.5
694.7
Current Ratio 5.11
ABMD's Current Ratio is ranked higher than
85% of the 502 Companies
in the Global Medical Devices industry.

( Industry Median: 2.70 vs. ABMD: 5.11 )
ABMD' s 10-Year Current Ratio Range
Min: 3.18   Max: 15.95
Current: 5.11

3.18
15.95
Quick Ratio 4.62
ABMD's Quick Ratio is ranked higher than
87% of the 502 Companies
in the Global Medical Devices industry.

( Industry Median: 1.98 vs. ABMD: 4.62 )
ABMD' s 10-Year Quick Ratio Range
Min: 2.56   Max: 15.43
Current: 4.62

2.56
15.43
Days Inventory 133.11
ABMD's Days Inventory is ranked higher than
77% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 174.47 vs. ABMD: 133.11 )
ABMD' s 10-Year Days Inventory Range
Min: 128.06   Max: 314.91
Current: 133.11

128.06
314.91
Days Sales Outstanding 48.58
ABMD's Days Sales Outstanding is ranked higher than
91% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 82.87 vs. ABMD: 48.58 )
ABMD' s 10-Year Days Sales Outstanding Range
Min: 48.41   Max: 160.07
Current: 48.58

48.41
160.07

Valuation & Return

vs
industry
vs
history
Price/Net Cash 40.30
ABMD's Price/Net Cash is ranked higher than
77% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 40.30 )
ABMD' s 10-Year Price/Net Cash Range
Min: 1.29   Max: 73.96
Current: 40.3

1.29
73.96
Price/Net Current Asset Value 28.30
ABMD's Price/Net Current Asset Value is ranked higher than
69% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 28.30 )
ABMD' s 10-Year Price/Net Current Asset Value Range
Min: 1.08   Max: 22.32
Current: 28.3

1.08
22.32
Price/Tangible Book 19.10
ABMD's Price/Tangible Book is ranked lower than
56% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 8.30 vs. ABMD: 19.10 )
ABMD' s 10-Year Price/Tangible Book Range
Min: 1   Max: 16.93
Current: 19.1

1
16.93
Price/DCF (Projected) 9.60
ABMD's Price/DCF (Projected) is ranked higher than
78% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 9.60 )
ABMD' s 10-Year Price/DCF (Projected) Range
Min: 4.39   Max: 41.45
Current: 9.6

4.39
41.45
Price/Median PS Value 2.20
ABMD's Price/Median PS Value is ranked higher than
52% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABMD: 2.20 )
ABMD' s 10-Year Price/Median PS Value Range
Min: 0.38   Max: 4.3
Current: 2.2

0.38
4.3
Price/Graham Number 11.30
ABMD's Price/Graham Number is ranked higher than
70% of the 575 Companies
in the Global Medical Devices industry.

( Industry Median: 0.00 vs. ABMD: 11.30 )
ABMD' s 10-Year Price/Graham Number Range
Min: 2.97   Max: 15.85
Current: 11.3

2.97
15.85
Earnings Yield (Greenblatt) 0.70
ABMD's Earnings Yield (Greenblatt) is ranked higher than
66% of the 493 Companies
in the Global Medical Devices industry.

( Industry Median: 1.40 vs. ABMD: 0.70 )
ABMD' s 10-Year Earnings Yield (Greenblatt) Range
Min: 0.1   Max: 3.7
Current: 0.7

0.1
3.7

Analyst Estimate

Mar15 Mar16 Mar17 Mar18
Revenue(Mil) 226 271 336 416
EPS($) 0.52 0.81 1.22 1.75
EPS without NRI($) 0.52 0.81 1.22 1.75

Business Description

Industry: Medical Devices » Medical Devices
Compare:MDT, SYK, SMA, ZMH, STJ » details
Traded in other countries:AIO.Germany,
Abiomed Inc is a Delaware corporation incorporated on June 4, 1987. The Company is engaged in providing mechanical circulatory support devices and it offers a continuum of care in heart recovery to heart failure patients. The Company develops, manufactures and markets proprietary products that are designed to enable the heart to rest, heal and recover by improving blood flow and/or performing the pumping function of the heart. Its products are used in the cardiac catheterization lab, or cath lab, by interventional cardiologists and in the heart surgery suite by heart surgeons for patients who are in need of hemodynamic support prophylactically or emergently before, during or after angioplasty or heart surgery procedures. The Companys product portfolio includes; Impella 2.5, Impella CP, Impella RP, AB5000, Symphony, and Impella 5.0 & Impella LD. The Companys Impella 2.5 catheter is a percutaneous micro heart pump with an integrated motor and sensors for use mainly in interventional cardiology. The device is designed mainly for use by interventional cardiologists to support patients in the cath lab who may require assistance to maintain their circulation. The Impella 5.0 catheter and Impella LD are percutaneous micro heart pumps with integrated motors and sensors for use mainly in the heart surgery suite. These devices are designed to support patients who require higher levels of circulatory support as compared to the Impella 2.5. The Impella RP is a percutaneous catheter-based axial flow pump that is designed to allow greater than four liters of flow per minute and to provide the flow and pressure needed to compensate for right heart failure. The Company manufactures & sells the AB5000 Circulatory Support System for the temporary support of acute heart failure patients in profound shock, including patients suffering from cardiogenic shock after a heart attack, post-cardiotomy cardiogenic shock, or myocarditis. The Company faces competition from Getinge (Maquet Cardiovascular), Teleflex Inc., Thoratec Corporation, HeartWare International Inc., Jarvik Heart, Terumo Heart, Inc. and CardiacAssist Inc. The Companys business is subject to extensive federal, state, local and foreign regulation.
» More Articles for ABMD

Headlines

Articles On GuruFocus.com
Impressive Numbers That Matter: Abiomed Inc (ABMD), Freescale Semiconductor Ltd (FSL), Apple Inc (AA Jan 28 2015 
Vycor Value Could be Unlocked with These Major Partnerships Dec 05 2014 
Weekly CFO Sells Highlight: USB, SGEN, CAH, ALXN, ABMD Jul 21 2013 
BSX and ABMD Highlight Increased Insider Buying in the Medical Technology Sector May 14 2013 
Weekly CFO Sells Highlight: BDSI, LNKD, VRSK, ABMD, AGX Jul 17 2012 
ABIOMED Inc. Reports Operating Results (10-Q) Feb 04 2011 
ABIOMED Inc. Reports Operating Results (10-Q) Aug 05 2010 
ABIOMED Inc. (ABMD) COO David M Weber sells 1,389 Shares May 25 2010 
ABIOMED Inc. (ABMD) President, CEO, Chairman Michael R Minogue sells 4,491 Shares May 25 2010 
Trade Setups for May 19, 2010 May 19 2010 


More From Other Websites
Inogen Gains despite Further Delay in Form 10-K Filing - Analyst Blog Apr 16 2015
Thoratec Hits 52-Week High on Favorable Developments - Analyst Blog Apr 16 2015
HeartWare Gets VAD Distribution Approval from Health Canada - Analyst Blog Apr 15 2015
Masimo to Launch Patient SafetyNet System with Iris, MyView - Analyst Blog Apr 14 2015
Intuitve Surgical's Product Line Strong, Hits 52-Week High - Analyst Blog Apr 14 2015
DexCom Launches CGM App on Apple Watch; Shares Rise - Analyst Blog Apr 13 2015
DexCom Hits 52-Week High on Q4 Results, Estimate Revision - Analyst Blog Apr 10 2015
AngioDynamics Lags Earnings on Lower Sales, View Tepid - Analyst Blog Apr 10 2015
Luminex (LMNX) Launches NxTAG RPP for Respiratory Testing - Analyst Blog Apr 07 2015
Thoratec Wins FDA Consent to Expand HeartMate III US Trial - Analyst Blog Apr 06 2015
IDEXX Banks on Strong CAG, Global Growth Continues - Analyst Blog Apr 01 2015
Inogen Fails 10-K Deadline; Files Form 12b-25 for Extra Time - Analyst Blog Apr 01 2015
Varian Medical: A Strong Sell on Tepid View, Estimate Revision - Analyst Blog Apr 01 2015
Luminex (LMNX) Commences Clinical Trials for ARIES System - Analyst Blog Mar 31 2015
Cepheid Ships Record Xpert MTB/RIF to Mark World TB Day - Analyst Blog Mar 30 2015
Adeptus Health Hits 52-Week High on Top-Line Strength - Analyst Blog Mar 30 2015
Varian (VAR) Showcases Edge Radiosurgey at 2015 ChinaMed - Analyst Blog Mar 27 2015
Hanger Goes Downhill on Moody's Rating Cut, NYSE Notice - Analyst Blog Mar 27 2015
Cepheid's Xpert Ebola Gets FDA's Nod for Emergency Use - Analyst Blog Mar 27 2015
Zacks Industry Outlook Highlights: Boston Scientific, Edwards Lifesciences, Natus Medical, Hologic... Mar 27 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
FEEDBACK